peptide0 listings

Tirzepatide + Cagrilintide

Tirzepatide/Cagrilintide Combination

Research combination of a dual GIP/GLP-1 agonist with an amylin analog.

Weight researchMetabolic research

/ research index

The research base

Research Maturity

★★★☆☆

3/5 — Volume of studies

Evidence Strength

★★★☆☆

3/5 — Quality of evidence

Investigational stacking of incretin and amylin pathways for additive metabolic research effects.

/ mechanism of action

How it works

Combines GIP/GLP-1 dual agonism with amylin receptor agonism across three complementary satiety pathways.

/ research dosing

Common research protocols

Range

Per-component titration (research-dependent)

Frequency

Weekly subcutaneous

Route

Subcutaneous

Cycle

Titrate components in parallel

Research notes

Combination research stacking incretin and amylin mechanisms. Protocols are individual to the research design.

References

Research combination — see component references

FOR RESEARCH USE ONLY. Doses listed are compiled from published research literature, FDA-approved drug labels, and well-documented research community practice. Not medical advice.

/ standalone use

As a solo compound

Combination research only; both components require titration.

/ side effects

What to know

Combined GI effects; titrate conservatively.

/ timeline

Realistic expectations

Effects build over months

FOR RESEARCH USE ONLY. Tirzepatide + Cagrilintide is intended for laboratory research and not for human consumption.